Dutalys is dedicated to developing advanced antibody-based drugs for the treatment of serious and life-threatening diseases.
Monoclonal antibodies have become some of the most important active ingredients in new drugs developed by the pharmaceutical industry, because they can be endowed with very useful natural properties and excellent specificity for their intended targets, thereby achieving good efficacy and a high level of safety for the patient.
What sets apart the novel antibody molecules developed by our team is a design that makes them uniquely suitable for the treatment of disease mechanisms and therapeutic targets, which are too complex for successful treatment with other more conventional antibodies. The antibodies are developed as part of our proprietary drug pipeline, or custom-made to order for pharmaceutical and biotech companies for utilisation as tailor-made active ingredients in their new drug candidates.
On 18th of December 2014 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it acquired Dutalys GmbH.
Under the terms of the agreement, Roche will make an upfront cash payment of USD 133.75 million to shareholders and make additional contingent payments of up to USD 355 million based on the achievement of certain predetermined milestones.
+43 1 9971832